Armata Pharmaceuticals, Inc. (ARMP)

US — Healthcare Sector
Peers: ARAV  ARDS  ANIX  PHGE  ALPN 

Automate Your Wheel Strategy on ARMP

With Tiblio's Option Bot, you can configure your own wheel strategy including ARMP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ARMP
  • Rev/Share 0.0341
  • Book/Share -1.4863
  • PB -1.3119
  • Debt/Equity -1.9888
  • CurrentRatio 0.1191
  • ROIC -0.2047

 

  • MktCap 70577325.0
  • FreeCF/Share -1.0025
  • PFCF -1.9456
  • PE -165.6347
  • Debt/Assets 1.2259
  • DivYield 0
  • ROE 0.0086

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

ARMP Soars 72% in a Month Following Infectious Disease Study Success
ARMP
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.

Read More
image for news ARMP Soars 72% in a Month Following Infectious Disease Study Success
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
ARMP
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral

All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy No treatment-related serious adverse events were observed with repetitive intravenous dosing LOS ANGELES , May 19, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous ("IV") administered multi-phage …

Read More
image for news Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
New Strong Sell Stocks for May 8th
ARMP, COLM, EFSI
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative

ARMP, COLM and EFSI have been added to the Zacks Rank #5 (Strong Sell) List on May 8, 2025.

Read More
image for news New Strong Sell Stocks for May 8th
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
ARMP
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral

Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trial LOS ANGELES , May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $4.65 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and …

Read More
image for news Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
New Strong Sell Stocks for April 28th
ARMP, CABO, CCS
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Negative

CCS, ARMP and CABO have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2025.

Read More
image for news New Strong Sell Stocks for April 28th

About Armata Pharmaceuticals, Inc. (ARMP)

  • IPO Date 1994-05-20
  • Website https://www.armatapharma.com
  • Industry Biotechnology
  • CEO Dr. Deborah L. Birx M.D.
  • Employees 60

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.